Exploring Spatial-Temporal Changes in <sup>18</sup>F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Glenn Liu(University of Wisconsin Carbone Cancer Center), Anupama Singh(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), William Duggan(Cleveland Clinic), Robert Jeraj(University of Wisconsin–Madison), Timothy Perk(University of Wisconsin–Madison), Jamie M. Sperger(University of Wisconsin–Madison), Alison Roth(University of Wisconsin–Madison), Katharina Modelska(FibroGen (United States)), Anthony R. Porcari(Pfizer (United States)), Elisabeth I. Heath(The Barbara Ann Karmanos Cancer Institute), Anna C. Ferrari(Rutgers, The State University of New Jersey), Scott B. Perlman(University of Wisconsin–Madison)
Cited by 29
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k